<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2024000200079</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.23000055</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Cost reduction for cancer drug treatment with a vial sharing strategy in a centralized preparation unit]]></article-title>
<article-title xml:lang="es"><![CDATA[Reducción de costos en el tratamiento de fármacos contra el cáncer mediante una estrategia de compartición de viales en una unidad de preparación centralizada]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Núñez]]></surname>
<given-names><![CDATA[Karla D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sarmiento-Sánchez]]></surname>
<given-names><![CDATA[Eduardo S.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tapia]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Venus]]></surname>
<given-names><![CDATA[Sunev]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cervantes-Sánchez]]></surname>
<given-names><![CDATA[Guadalupe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cárdenas-Cárdenas]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Maldonado]]></surname>
<given-names><![CDATA[Edgar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Médico Nacional 20 de Noviembre, ISSSTE Department of Pharmacy ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Médico Nacional 20 de Noviembre, ISSSTE Medical Oncology Service ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>23</volume>
<numero>2</numero>
<fpage>79</fpage>
<lpage>83</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2024000200079&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2024000200079&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2024000200079&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Rising cancer rates and expensive drugs have inflated treatment costs. Medication wastage constitutes 5% of drug expenditure. Effective cost containment strategies are essential.  Objective: To implement and assess a cost-cutting strategy for oncology drugs.  Methods: Doses and quantities of oncology drugs were analyzed from January to June of 2022, calculating the total usage and costs by comparing with a decentralized system to estimate the economic impact.  Results: Sharing vials achieved a savings of $9,000,705.64MNX. Centralized preparation totaled $52,775,243.24MNX, with a 14% reduction in expenses.  Discussion: This pioneering study in Mexico aligns with similar reductions in other countries, underscoring the importance of applying cost containment strategies in developing nations.  Conclusion: Implementing a centralized preparation unit and vial sharing offer economic benefits, with further research needed to optimize their effectiveness.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: El aumento de casos de cáncer y los costosos tratamientos incrementan los gastos sanitarios. Se desperdician medicamentos equivalentes al 5% del gasto anual. Es importante implementar estrategias de contención de costos.  Objetivo: Implementar y evaluar una estrategia de reducción de costos en medicamentos oncológicos.  Métodos: Se analizaron dosis y cantidades de medicamentos oncológicos de enero a junio de 2022, calculando el uso total y costos comparando con un sistema descentralizado para estimar el impacto económico.  Resultados: Compartir viales logró un ahorro de $9,000,705.64MNX. La preparación centralizada totalizó $52,775,243.24MNX, con una reducción del 14% en gastos.  Discusión: Este estudio pionero en México coincide con reducciones similares en otros países, resaltando la importancia de aplicar estrategias de contención de costos en países en desarrollo.  Conclusión: La implementación de una unidad de preparación centralizada y la compartición de viales ofrecen beneficios económicos. Se requiere investigación adicional para optimizar su eficacia.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Pharmacoeconomics]]></kwd>
<kwd lng="en"><![CDATA[Cost savings]]></kwd>
<kwd lng="en"><![CDATA[Centralized preparation unit]]></kwd>
<kwd lng="en"><![CDATA[Vial sharing]]></kwd>
<kwd lng="en"><![CDATA[Oncology medications]]></kwd>
<kwd lng="es"><![CDATA[Farmacoeconomía]]></kwd>
<kwd lng="es"><![CDATA[Ahorro de costos]]></kwd>
<kwd lng="es"><![CDATA[Unidad de preparación centralizada]]></kwd>
<kwd lng="es"><![CDATA[Compartición de viales]]></kwd>
<kwd lng="es"><![CDATA[Medicamentos oncológicos]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schubert]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Torrance]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canada's new guidelines for the economic evaluation of pharmaceuticals]]></article-title>
<source><![CDATA[Med Care]]></source>
<year>1996</year>
<volume>34</volume>
<page-range>S77-86</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walley]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Haycox]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacoeconomics:basic concepts and terminology]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>1997</year>
<volume>43</volume>
<page-range>343-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fasola]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Aprile]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Marini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Follador]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mansutti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Miscoria]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug waste minimization as an effective strategy of cost-containment in oncology]]></article-title>
<source><![CDATA[BMC Health Serv Res]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>57</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soto Álvarez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudios de farmacoeconomía:¿por qué, cómo, cuándo y para qué?]]></article-title>
<source><![CDATA[Medifam]]></source>
<year>2001</year>
<volume>11</volume>
<page-range>147-55</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Laversanne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2021</year>
<volume>71</volume>
<page-range>209-49</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fasola]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Aita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Follador]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tosolini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mattioni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug waste minimisation and cost-containment in medical oncology:two-year results of a feasibility study]]></article-title>
<source><![CDATA[BMC Health Serv Res]]></source>
<year>2008</year>
<volume>8</volume>
<page-range>70</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El Gasto Global en Fármacos Oncológicos Superarálos 800.000 Millones en los Próximos Cuatro Años]]></article-title>
<source><![CDATA[El Español]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>Gobierno de México</collab>
<source><![CDATA[Gobierno Federal Adquiere Más de 2 Mil 600 Millones de Piezas de Medicamentos e Insumos]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[da Silva]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A preliminary analysis of the reduction of chemotherapy waste in the treatment of cancer with centralization of drug preparation]]></article-title>
<source><![CDATA[Rev Bras Anestesiol]]></source>
<year>2011</year>
<volume>61</volume>
<page-range>368-75</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Núñez]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Salar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A preliminary analysis of the reduction of chemotherapy waste in the treatment of cancer with centralization of drug preparation]]></article-title>
<source><![CDATA[J Oncol Pharm Pract]]></source>
<year>2021</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>368-74</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matsuo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nomura]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Uchiyama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Miyazaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Imakyure]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital]]></article-title>
<source><![CDATA[BMC Health Serv Res]]></source>
<year>2020</year>
<volume>20</volume>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fukudo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ishikawa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mishima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ono]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matsumoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tasaki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world nivolumab wastage and leftover drug stability assessment to facilitate drug vial optimization for cost savings]]></article-title>
<source><![CDATA[JCO Oncol Pract]]></source>
<year>2020</year>
<volume>16</volume>
<page-range>42</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Phimarn]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Saramunee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Leelathanalerk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Srimongkon]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chanasopon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Phumart]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic evaluation of pharmacy services:a systematic review of the literature (2016&#8211;2020)]]></article-title>
<source><![CDATA[Int J Clin Pharm]]></source>
<year>2023</year>
<volume>45</volume>
<page-range>1326-48</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Strategies for cost reduction in healthcare:a comprehensive review]]></article-title>
<source><![CDATA[J Healthc Manag]]></source>
<year>2023</year>
<volume>10</volume>
<page-range>75-86</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Charbonneau]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Prica]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Financial Impact of Cancer Drug Wastage and Potential Cost Savings From Mitigation Strategies]]></article-title>
<source><![CDATA[J Oncol Pract]]></source>
<year>2017</year>
<volume>13</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>e652</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Solimando]]></surname>
<given-names><![CDATA[JRDA]]></given-names>
</name>
<name>
<surname><![CDATA[Grollman]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Pang]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Chasick]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Hightman]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost savings realized by use of the PhaSeal, closed-system transfer device for preparation of antineoplastic agents]]></article-title>
<source><![CDATA[J Oncol Pharm Pract]]></source>
<year>2013</year>
<volume>19</volume>
<page-range>338-47</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of observational studies in healthcare research]]></article-title>
<source><![CDATA[J Med Res]]></source>
<year>2019</year>
<volume>5</volume>
<page-range>47-52</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Generalizability of research findings in healthcare settings:a systematic review]]></article-title>
<source><![CDATA[J Health Serv Res]]></source>
<year>2021</year>
<volume>8</volume>
<page-range>189-98</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[PQ]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resource management in oncology:current practices and future directions]]></article-title>
<source><![CDATA[J Oncol Pract]]></source>
<year>2020</year>
<volume>16</volume>
<page-range>187-94</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bahreini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gholizadeh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gulin Gedik]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Yousefi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Janati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Components of contributing conditions to strengthen health system management and leadership capacity building:a systematic review and decision-making framework]]></article-title>
<source><![CDATA[Leadersh Health Serv]]></source>
<year>2021</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>527-45</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
